Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14


Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma.

Arend RC, Londoño AI, Montgomery AM, Smith HJ, Dobbin ZC, Katre AA, Martinez A, Yang ES, Alvarez RD, Huh WK, Bevis KS, Straughn JM Jr, Estes JM, Novak L, Crossman DK, Cooper SJ, Landen CN, Leath CA 3rd.

Mol Cancer Res. 2018 May;16(5):813-824. doi: 10.1158/1541-7786.MCR-17-0594. Epub 2018 Mar 9.


Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer.

Cornelison R, Dobbin ZC, Katre AA, Jeong DH, Zhang Y, Chen D, Petrova Y, Llaneza DC, Steg AD, Parsons L, Schneider DA, Landen CN.

Clin Cancer Res. 2017 Nov 1;23(21):6529-6540. doi: 10.1158/1078-0432.CCR-17-0282. Epub 2017 Aug 4.


Ovarian and cervical cancer patient derived xenografts: The past, present, and future.

Boone JD, Dobbin ZC, Straughn JM Jr, Buchsbaum DJ.

Gynecol Oncol. 2015 Aug;138(2):486-91. doi: 10.1016/j.ygyno.2015.05.022. Epub 2015 May 27. Review.


Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer.

Erickson BK, Kinde I, Dobbin ZC, Wang Y, Martin JY, Alvarez RD, Conner MG, Huh WK, Roden RB, Kinzler KW, Papadopoulos N, Vogelstein B, Diaz LA Jr, Landen CN Jr.

Obstet Gynecol. 2014 Nov;124(5):881-5. doi: 10.1097/AOG.0000000000000484.


Proteasome inhibition reverses hedgehog inhibitor and taxane resistance in ovarian cancer.

Steg AD, Burke MR, Amm HM, Katre AA, Dobbin ZC, Jeong DH, Landen CN.

Oncotarget. 2014 Aug 30;5(16):7065-80.


Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN.

Oncotarget. 2014 Sep 30;5(18):8750-64.


An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN.

Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15.


Isolation and characterization of potential cancer stem cells from solid human tumors--potential applications.

Dobbin ZC, Landen CN.

Curr Protoc Pharmacol. 2013 Dec 2;63:Unit 14.28.. doi: 10.1002/0471141755.ph1428s63.


The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer.

Dobbin ZC, Landen CN.

Int J Mol Sci. 2013 Apr 15;14(4):8213-27. doi: 10.3390/ijms14048213. Review.


Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN.

Clin Cancer Res. 2013 Jan 1;19(1):170-82. doi: 10.1158/1078-0432.CCR-12-1045. Epub 2012 Nov 12.


SUZ12 promotes human epithelial ovarian cancer by suppressing apoptosis via silencing HRK.

Li H, Cai Q, Wu H, Vathipadiekal V, Dobbin ZC, Li T, Hua X, Landen CN, Birrer MJ, Sánchez-Beato M, Zhang R.

Mol Cancer Res. 2012 Nov;10(11):1462-72. doi: 10.1158/1541-7786.MCR-12-0335. Epub 2012 Sep 10.


Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN.

Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058. Epub 2012 May 2.


Tyrosine-phosphorylated caveolin-1 (Tyr-14) increases sensitivity to paclitaxel by inhibiting BCL2 and BCLxL proteins via c-Jun N-terminal kinase (JNK).

Shajahan AN, Dobbin ZC, Hickman FE, Dakshanamurthy S, Clarke R.

J Biol Chem. 2012 May 18;287(21):17682-92. doi: 10.1074/jbc.M111.304022. Epub 2012 Mar 20.


Stem cell pathways contribute to clinical chemoresistance in ovarian cancer.

Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M, Landen CN.

Clin Cancer Res. 2012 Feb 1;18(3):869-81. doi: 10.1158/1078-0432.CCR-11-2188. Epub 2011 Dec 5.

Supplemental Content

Loading ...
Support Center